

# Anti-FGFR3 hlgG1 Reference Antibody(Vofabio)

## Product Information


<b>Product Name</b>	Anti-FGFR3 hlgG1 Reference Antibody(Vofabio)
<b>Storage temp.</b>	Store at 2-8°C short term (1-2 weeks).Store at $\leq -20^{\circ}\text{C}$ long term. Avoid repeated freeze-thaw.
<b>Catalog# / Size</b>	<b>GM-88323MAB-1mg / 1 mg</b> <b>GM-88323MAB-5mg / 5 mg</b> <b>GM-88323MAB-25mg / 5 mg*5 vials</b> <b>GM-88323MAB-50mg / 50 mg</b> <b>GM-88323MAB-100mg / 50 mg*2 vials</b>

## Antibody Information

<b>Expression System</b>	CHO
<b>Aggregation</b>	< 5% as determined by SEC-HPLC
<b>Purity</b>	> 95% as determined by SDS-PAGE
<b>Endotoxin</b>	< 1 EU/mg, determined by LAL gel clotting assay
<b>Sterility</b>	0.2 $\mu\text{m}$ Filtered
<b>Target</b>	FGFR3
<b>Alternative Names</b>	ACH, CD333, CEK2, HSFGR3EX, JTK4
<b>Clone</b>	Vofatamab
<b>Source/Isotype</b>	Human IgG1, Kappa
<b>Application</b>	Flow Cytometry
<b>Description</b>	Vofatamab is an anti-FGFR3 monoclonal antibody that acts as an FGFR3 antagonist to block activation of wild-type and gene-activated receptors, it is used to treat metastatic urothelial cancer (MUC, a type of bladder cancer) that carries FGFR3 mutations or fusion genes, which are present in 15% to 20% of patients with advanced disease. The drug inhibits tumor growth by specifically targeting the FGFR3 signaling pathway and has shown significant efficacy in clinical trials in combination with docetaxel or PD-1 inhibitors.
<b>Formulation</b>	phosphate-buffered solution, pH 7.2-7.4.


## Data Examples

### SDS-PAGE



On SDS-PAGE under reducing (R)/non-reducing(N-R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

### SEC-HPLC



The purity of this product is more than 95% verified by SEC-HPLC.

Flow Cytometry

H\_FGFR3C HEK-293 Cell Line (Catalog # GM-C41513) was stained with Anti-FGFR3 hlgG1 Reference Antibody(Vofabio) (Catalog # GM-88323MAB) or isotype control antibody, followed by anti-Human IgG APC-conjugated Secondary Antibody.




Fig. FACS

Genomeditech